
Sign up to save your podcasts
Or


Valneva CEO Thomas Lingelbach walks us through this program by describing how the vaccine is designed and how the study has been conducted. Plus, his comments on FDA's rescinding of the company's Chikungunya virus vaccine.
By BiotechTV4.3
66 ratings
Valneva CEO Thomas Lingelbach walks us through this program by describing how the vaccine is designed and how the study has been conducted. Plus, his comments on FDA's rescinding of the company's Chikungunya virus vaccine.

3,376 Listeners

421 Listeners

1,650 Listeners

947 Listeners

124 Listeners

321 Listeners

211 Listeners

6,443 Listeners

62 Listeners

10,020 Listeners

86 Listeners

34 Listeners

21 Listeners

0 Listeners

4 Listeners

3 Listeners

5 Listeners

37 Listeners